SEC Form 4 · accession 0001182471-26-000002
Lyell Immunopharma, Inc. · LYEL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William Jl Rieflin
Director
Period of report
Jun 10, 2026
Accepted (ET)
Jun 12, 2026 · 4:25 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001806952
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option (right to buy)F1 | $13.22 | Jun 10, 2026 | A | 9,250 | A | — | Jun 9, 2036 | Common Stock | 9,250 | 9,250 | D |
Explanation of responses
- F1The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date.